<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00667459</url>
  </required_header>
  <id_info>
    <org_study_id>PRESTIGE® LP Protocol, #P03-03</org_study_id>
    <nct_id>NCT00667459</nct_id>
  </id_info>
  <brief_title>Study of Safety &amp; Effectiveness of PRESTIGE® LP Cervical Disc vs. Anterior Cervical Fusion in Cervical DDD</brief_title>
  <official_title>A Prospective, Multicenter, Controlled Clinical Trial of an Artificial Cervical Disc LP at a Single Level for Symptomatic Cervical Disc Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Spinal and Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Spinal and Biologics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to evaluate the safety and effectiveness of the
      PRESTIGE® LP Cervical Disc as a method of treating patients with symptoms of cervical
      degenerative disc disease at a single level from C3-C4 to C6-C7.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pivotal clinical trial was conducted to compare treatment data of the investigational
      implant device,the PRESTIGE® LP Cervical Disc, with a control patient group receiving a
      plate. The PRESTIGE® LP Cervical Disc devices were implanted using an anterior surgical
      approach. Data from control patients receiving anterior cervical discectomy and fusion with
      an ATLANTIS Anterior Cervical Plate from the initial Artificial Cervical Disc study
      (NCT00642876) were compared as both treatment groups receive single-level surgical treatment
      from C3-C4 to C6-C7 for symptomatic cervical degenerative disc disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Overall Success</measure>
    <time_frame>24 months</time_frame>
    <description>Rate of overall success is reported as the percentage of participants who met all of the following criteria:
Postoperative Neck Disability Index score improvement of at least a 15-points from preoperative;
Maintenance or improvement in neurological status;
Disc height success which was defined as either the anterior or posterior measurements meeting the criteria of &quot;Postoperative Height - 6 Week Postoperative Height ≥ -2mm&quot;;
No serious adverse event classified as implant associated or implant/surgical procedure associated; and
No secondary surgical procedure classified as a &quot;failure.&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success Rate of Neck Disability Index</measure>
    <time_frame>24 months</time_frame>
    <description>Success rate of Neck Disability Index is reported as the percentage of participants whose neck disability index score met: Pre-treatment Score - Post-treatment Score ≥ 15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success Rate of Neurological Status</measure>
    <time_frame>24 months</time_frame>
    <description>Success rate of neurological status is reported as the percentage of participants who met neurological success defined as maintenance or improvement in all sections (motor, sensory, and reflexes) for the time period evaluated. In order for a section to be considered a success, each element in the section must remain the same or improve from the time of the preoperative evaluation to the time period evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Disc Height Success</measure>
    <time_frame>24 months</time_frame>
    <description>Disc height was assessed by determining the Functional Spinal Unit (FSU) height. The rate of disc height success is reported as the percentage of participants whose disc height for each level based on either the anterior or posterior measurements met the following criterion: Postoperative Height - 6 Week Postoperative Height &gt;= -2mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neck Pain Success Rate</measure>
    <time_frame>24 months</time_frame>
    <description>Numerical rating scales were used to evaluate pain intensity and frequency. The pain score (0 min, 100 max) was derived by multiplying the numerical rating scores from the pain intensity (0-10, with a score of 0 representing &quot;no pain&quot; and a score of 10 representing &quot;pain as bad as it could be.&quot;) and frequency scales (0-10, with a score of 0 being &quot;pain none of the time&quot; and a score of 10 being &quot;pain all of the time&quot;). Neck pain success rate is reported as the percentage of participants whose neck pain improvement met: Preoperative Score - Postoperative Score &gt; 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm Pain Success Rate</measure>
    <time_frame>24 months</time_frame>
    <description>Numerical rating scales were used to evaluate pain intensity and frequency. The pain score (0 min, 100 max) was derived by multiplying the numerical rating scores from the pain intensity (0-10, with a score of 0 representing &quot;no pain&quot; and a score of 10 representing &quot;pain as bad as it could be.&quot;) and frequency scales (0-10, with a score of 0 being &quot;pain none of the time&quot; and a score of 10 being &quot;pain all of the time&quot;). Arm pain success rate is reported as the percentage of participants whose arm pain improvement met: Preoperative Score - Postoperative Score &gt; 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success Rate of SF-36 PCS</measure>
    <time_frame>24 months</time_frame>
    <description>Success rate of SF-36 Health Survey include two components: the success rate of a physical component summary (PCS) and the success rate of a mental component summary (MCS). The success of SF-36 PCS was defined as: Post Score - Pre Score &gt;= 0. The Success rate of SF-36 PCS is reported as the percentage of the participants who were classified as a success for SF-36 PCS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success Rate of SF-36 MCS</measure>
    <time_frame>24 months</time_frame>
    <description>Success rate of SF-36 Health Survey include two components: the success rate of a physical component summary (PCS) and the success rate of a mental component summary (MCS). The success of SF-36 MCS were defined as: Post Score - Pre Score &gt;= 0. The Success rate of SF-36 MCS is reported as the percentage of the participants who were classified as a success for SF-36 MCS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gait Success Rate</measure>
    <time_frame>24 months</time_frame>
    <description>Patient's gait was assessed by using Nurick's classification, and indicated either as normal or graded on a scale of 0 to 5. Success was defined as maintenance or improvement in the postoperative status as compared to the preoperative condition: Preoperative Score - Postoperative Score &gt;= 0. The gait success rate is reported as the percentage of participants who had gait success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative Time</measure>
    <time_frame>Time of operation, approximately 1.5 hrs.</time_frame>
    <description>Operative time was recorded from skin incision to wound closure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Loss</measure>
    <time_frame>During the time of operation, approximately 1.5 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Stay</measure>
    <time_frame>During the time of hospital stay, average of 1 day.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Secondary Surgery at Index Level</measure>
    <time_frame>24 months post-operation</time_frame>
    <description>Secondary surgical procedures at the index level included revisions, removals, supplemental fixations and reoperations. Rate of secondary surgery at index level is reported as percentage of patients who had secondary surgeries at index level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Neck Disability Index Score From Baseline</measure>
    <time_frame>Baseline and 24 months post-operation</time_frame>
    <description>The self-administered Neck Disability Index (NDI) Questionnaire was used to assess patient neck pain and ability to function. The NDI scale ranges from 0-100. The best score is 0 (no disability) and worst is 100 (maximum disability). Change of NDI was defined as NDI at 24 month minus NDI at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Neck Pain Score From Baseline</measure>
    <time_frame>Baseline and 24 months post-operation</time_frame>
    <description>Numerical rating scales were used to evaluate neck pain intensity and frequency. Patients rated their neck pain intensity on a scale from 0-10, with a score of 0 representing &quot;no pain&quot; and a score of 10 representing &quot;pain as bad as it could be.&quot; Similarly, patients recorded their neck pain frequency on a scale from 0-10, with a score of 0 being &quot;pain none of the time&quot; and a score of 10 being &quot;pain all of the time.&quot; The total neck pain score (0 to100) was the product of pain intensity and frequency scores. Change of neck pain score was defined as neck pain score at 24 months minus neck pain score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Arm Pain Score From Baseline</measure>
    <time_frame>Baseline and 24 months post-operation</time_frame>
    <description>Numerical rating scales were also used to evaluate arm pain intensity and frequency. Patients rated their arm pain intensity on a scale from 0-10, with a score of 0 representing &quot;no pain&quot; and a score of 10 representing &quot;pain as bad as it could be.&quot; Similarly, patients recorded their arm pain frequency on a scale from 0-10, with a score of 0 being &quot;pain none of the time&quot; and a score of 10 being &quot;pain all of the time.&quot; The total arm pain score (0 to 100) was the product of pain intensity and frequency scores. Change of arm pain score was defined as arm pain score at 24 months minus arm pain score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of General Health Status -- SF-36 PCS From Baseline</measure>
    <time_frame>Baseline and 24 months post-operation</time_frame>
    <description>The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) was used to assess general health status. The SF-36 results were summarized into two components, a physical component summary (PCS) and a mental component summary (MCS). The score for PCS was between 0 and 100, with higher scores denoting better quality of life. Change of SF-36 PCS score was defined as PCS score at 24 months minus PCS score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of General Health Status -- SF-36 MCS From Baseline</measure>
    <time_frame>Baseline and 24 months post-operation</time_frame>
    <description>The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) was used to assess general health status. The SF-36 results were summarized into two components, a physical component summary (PCS) and a mental component summary (MCS). The score for MCS was between 0 and 100, with higher scores denoting better quality of life. Change of SF-36 MCS score was defined as MCS score at 24 months minus MCS score at baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">280</enrollment>
  <condition>Cervical Degenerative Disc Disease</condition>
  <arm_group>
    <arm_group_label>Investigational</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRESTIGE® LP Cervical Disc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control patients who received a ACDF fusion treatment from a previous IDE trial (NCT00642876)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PRESTIGE® LP Cervical Disc</intervention_name>
    <description>The PRESTIGE® LP Cervical Disc was inserted into the intervertebral disc space of the cervical spine using the anterior surgical approach.</description>
    <arm_group_label>Investigational</arm_group_label>
    <other_name>PRESTIGE® LP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ATLANTIS Anterior Cervical Plate</intervention_name>
    <description>Anterior cervical discectomy and fusion with ATLANTIS plate for control group</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>ATLANTIS plate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has cervical degenerative disc disease as defined as: intractable radiculopathy and/or
             myelopathy with at least one of the following items producing symptomatic nerve root
             and/or spinal cord compression that is documented by patient history: a) herniated
             disc; b) osteophyte formation

          -  One level requiring surgical treatment

          -  C3-C4 disc to C6-C7 disc level involvement

          -  Unresponsive to non-operative treatment for six weeks or presence of progressive
             symptoms or signs of cord compression

          -  No previous surgical procedures at the involved level or any planned surgical
             procedure at the involved or adjacent level.

          -  Preop Neck Disability index score ≥ 30

          -  Preop Neck Pain score of ≥ 20 based on the Preop Neck &amp; Arm Pain Questionnaire

          -  Not pregnant at time of surgery

          -  Willing and able to comply with study plan and able to understand and sign patient
             informed consent

        Exclusion Criteria:

          -  Any other cervical spinal condition requiring surgical treatment at the involved level

          -  Documented or diagnosed cervical instability defined by radiographs showing

               1. Sagittal plane translation &gt; 3.5mm or

               2. Sagittal plane angulation &gt; 20 degrees.

          -  More than one cervical level requiring surgery

          -  A fused level adjacent to the level to be treated

          -  Severe pathology of the facet joint of involved bodies

          -  Previous surgery at the involved level

          -  Previously diagnosed osteopenia or osteomalacia

          -  Any of the following that may be associated with an osteoporosis diagnosis (if &quot;Yes&quot;
             to any of these, a DEXA Scan will be required to determine eligibility)

               1. Postmenopausal non-Black female over 60 years of age and weighs less than 140
                  pounds

               2. Postmenopausal female that has sustained a non-traumatic hip, spine, or wrist
                  fracture

               3. Male over the age of 70

               4. Male over the age of 60 that has sustained a non-traumatic hip or spine fracture.

        If the level of Bone Mineral Density is a T score of -3.5 or lower or a T score of -2.5 or
        lower with the vertebral crush fracture, then the patient is excluded.

          -  Presence of spinal metastases

          -  Overt or active bacterial infection, either local or systemic

          -  Severe insulin dependent diabetes

          -  Chronic or acute renal failure or history of renal disease

          -  Temperature &gt; 101º F oral at surgery

          -  Documented allergy to stainless steel, titanium or a titanium alloy

          -  Mentally incompetent

          -  Is a prisoner

          -  Is pregnant

          -  Is an alcohol and/or drug abuser

          -  Has received drugs which may interfere with bone metabolism within 2 weeks prior to
             the planned surgery date (steroids, methotrexate), excluding routine preop
             anti-inflammatories)

          -  A history of endocrine or metabolic disorder known to affect osteogenesis

          -  A condition that requires postop medications that interfere with the stability of the
             implant (steroids). This does not include low dose aspirin therapy.

          -  Received treatment with an investigational therapy within 28 days prior to surgery or
             planned for 16 weeks following implantation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Emory Orthopaedics and Spine Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hughston Clinic, P.C.</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coeur d'Alene Spine and Brain, PLLC</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Illinois Neuroscience</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Spine</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OrthoIndy</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedar Neurological Surgeons, PC</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sports Medicine North</name>
      <address>
        <city>Peabody</city>
        <state>Massachusetts</state>
        <zip>01960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Orthopaedic Center of St. Louis</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Springfield Neurological Institute</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buffalo Neurosurgery Group</name>
      <address>
        <city>West Seneca</city>
        <state>New York</state>
        <zip>14224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroSpine Institute, LLC</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials for South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Orthopaedic Group</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain and Spine Center of Texas, L.L.P.</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia,Neurosurgery Department</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2008</study_first_submitted>
  <study_first_submitted_qc>April 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2008</study_first_posted>
  <results_first_submitted>August 22, 2014</results_first_submitted>
  <results_first_submitted_qc>September 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 22, 2014</results_first_posted>
  <disposition_first_submitted>July 17, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>July 17, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 25, 2012</disposition_first_posted>
  <last_update_submitted>January 22, 2015</last_update_submitted>
  <last_update_submitted_qc>January 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical Disc</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Investigational</title>
          <description>PRESTIGE® LP Cervical Disc</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="280"/>
                <participants group_id="P2" count="265"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="272"/>
                <participants group_id="P2" count="220"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Investigational</title>
          <description>PRESTIGE® LP Cervical Disc</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="280"/>
            <count group_id="B2" value="265"/>
            <count group_id="B3" value="545"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.5" spread="8.8"/>
                    <measurement group_id="B2" value="43.9" spread="8.8"/>
                    <measurement group_id="B3" value="44.2" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="271"/>
                    <measurement group_id="B2" value="243"/>
                    <measurement group_id="B3" value="514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>in.</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.7" spread="4.1"/>
                    <measurement group_id="B2" value="67.5" spread="4.2"/>
                    <measurement group_id="B3" value="67.6" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>lbs.</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186.9" spread="45.0"/>
                    <measurement group_id="B2" value="184.7" spread="41.5"/>
                    <measurement group_id="B3" value="185.8" spread="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marital Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Single</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Married</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                    <measurement group_id="B2" value="204"/>
                    <measurement group_id="B3" value="393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Divorced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Separated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Widowed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education Level</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; High School</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High School</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; High School</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                    <measurement group_id="B2" value="173"/>
                    <measurement group_id="B3" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Worker's Compensation Case</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="248"/>
                    <measurement group_id="B2" value="230"/>
                    <measurement group_id="B3" value="478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Unresolved Spinal Litigation</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="246"/>
                    <measurement group_id="B2" value="233"/>
                    <measurement group_id="B3" value="479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tobacco Used</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                    <measurement group_id="B2" value="173"/>
                    <measurement group_id="B3" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Used</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preop Work Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Overall Success</title>
        <description>Rate of overall success is reported as the percentage of participants who met all of the following criteria:
Postoperative Neck Disability Index score improvement of at least a 15-points from preoperative;
Maintenance or improvement in neurological status;
Disc height success which was defined as either the anterior or posterior measurements meeting the criteria of “Postoperative Height - 6 Week Postoperative Height ≥ -2mm”;
No serious adverse event classified as implant associated or implant/surgical procedure associated; and
No secondary surgical procedure classified as a &quot;failure.&quot;</description>
        <time_frame>24 months</time_frame>
        <population>The primary analysis dataset for this study consists of all subjects who received study devices and completed the initial surgical procedures. The analysis was based on the observed data and missing data due to lost-to-follow-ups were imputed. For the primary endpoint, the analysis consists of 226 investigational subjects and 171 control subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational</title>
            <description>PRESTIGE® LP Cervical Disc</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Overall Success</title>
          <description>Rate of overall success is reported as the percentage of participants who met all of the following criteria:
Postoperative Neck Disability Index score improvement of at least a 15-points from preoperative;
Maintenance or improvement in neurological status;
Disc height success which was defined as either the anterior or posterior measurements meeting the criteria of “Postoperative Height - 6 Week Postoperative Height ≥ -2mm”;
No serious adverse event classified as implant associated or implant/surgical procedure associated; and
No secondary surgical procedure classified as a &quot;failure.&quot;</description>
          <population>The primary analysis dataset for this study consists of all subjects who received study devices and completed the initial surgical procedures. The analysis was based on the observed data and missing data due to lost-to-follow-ups were imputed. For the primary endpoint, the analysis consists of 226 investigational subjects and 171 control subjects.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.4"/>
                    <measurement group_id="O2" value="63.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis H0: p1 + d ≤ p0, and the alternative hypothesis is Ha: p1 + d &gt; p0 where P0 and P1 are the overall success rates in the control group and the investigational group respectively, and d is the non-inferiority margin. The analyses used Bayesian methodology. Should the posterior probability P(p1 – p0 &gt; -d | data) be at least 0.95, then the null noninferiority hypothesis will be rejected, and non-inferiority of the investigational device to the control will be claimed.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin is 0.1.</non_inferiority_desc>
            <p_value>0.995</p_value>
            <p_value_desc>The posterior probably of non-inferiority was calculated and presented instead of the p-value.</p_value_desc>
            <method>Bayesian logistic model</method>
            <method_desc>The propensity score method was used to adjust possible effects on outcomes caused by differences in baseline characteristic due to non-randomization.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.032</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.070</ci_lower_limit>
            <ci_upper_limit>0.134</ci_upper_limit>
            <estimate_desc>The posterior mean of P1-P0, along with the corresponding 95% highest posterior density (HPD) interval was presented instead of the usual 95% CI.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority comparison of success rates in two treatment groups was a secondary objective of this trial. Superiority analysis was performed if non-inferiority was demonstrated. If the posterior probability is at least 0.95, a claim of superiority can be made.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.736</p_value>
            <p_value_desc>The posterior probably of superiority was calculated and presented instead of the p-value.</p_value_desc>
            <method>Bayesian logistic model</method>
            <method_desc>The propensity score method was used to adjust possible effects on outcomes caused by differences in baseline characteristic due to non-randomization.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Success Rate of Neck Disability Index</title>
        <description>Success rate of Neck Disability Index is reported as the percentage of participants whose neck disability index score met: Pre-treatment Score - Post-treatment Score ≥ 15.</description>
        <time_frame>24 months</time_frame>
        <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable NDI success status at 24 months, which leads to 270 subjects in the investigational group and 219 subjects in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational</title>
            <description>PRESTIGE® LP Cervical Disc</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rate of Neck Disability Index</title>
          <description>Success rate of Neck Disability Index is reported as the percentage of participants whose neck disability index score met: Pre-treatment Score - Post-treatment Score ≥ 15.</description>
          <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable NDI success status at 24 months, which leads to 270 subjects in the investigational group and 219 subjects in the control group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.8"/>
                    <measurement group_id="O2" value="80.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis H0: p1 + d ≤ p0, and the alternative hypothesis is Ha: p1 + d &gt; p0 where P0 and P1 are the success rates of NDI in the control group and the investigational group respectively, and d is the non-inferiority margin. The analyses used Bayesian methodology. Should the posterior probability P(p1 – p0 &gt; -d | data) be at least 0.95, then the null noninferiority hypothesis will be rejected, and non-inferiority of the investigational group will be claimed for this endpoint.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin is 0.1.</non_inferiority_desc>
            <p_value>1.0</p_value>
            <p_value_desc>The posterior probably of non-inferiority was calculated and presented instead of the p-value.</p_value_desc>
            <method>Bayesian logistic model</method>
            <method_desc>The propensity score method was used to adjust possible effects on outcomes caused by differences in baseline characteristic due to non-randomization.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.048</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.020</ci_lower_limit>
            <ci_upper_limit>0.118</ci_upper_limit>
            <estimate_desc>The posterior mean of P1-P0, along with the corresponding 95% highest posterior density (HPD) interval was presented instead of the usual 95% CI.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority comparison of success rates in two treatment groups was a secondary objective of this trial. Superiority analysis was performed if non-inferiority was demonstrated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.912</p_value>
            <p_value_desc>The posterior probably of superiority was calculated and presented instead of the p-value.</p_value_desc>
            <method>Bayesian logistic model</method>
            <method_desc>The propensity score method was used to adjust possible effects on outcomes caused by differences in baseline characteristic due to non-randomization.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Success Rate of Neurological Status</title>
        <description>Success rate of neurological status is reported as the percentage of participants who met neurological success defined as maintenance or improvement in all sections (motor, sensory, and reflexes) for the time period evaluated. In order for a section to be considered a success, each element in the section must remain the same or improve from the time of the preoperative evaluation to the time period evaluated.</description>
        <time_frame>24 months</time_frame>
        <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable neurological success status at 24 months, which leads to 270 subjects in the investigational group and 220 subjects in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational</title>
            <description>PRESTIGE® LP Cervical Disc</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rate of Neurological Status</title>
          <description>Success rate of neurological status is reported as the percentage of participants who met neurological success defined as maintenance or improvement in all sections (motor, sensory, and reflexes) for the time period evaluated. In order for a section to be considered a success, each element in the section must remain the same or improve from the time of the preoperative evaluation to the time period evaluated.</description>
          <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable neurological success status at 24 months, which leads to 270 subjects in the investigational group and 220 subjects in the control group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3"/>
                    <measurement group_id="O2" value="83.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis H0: p1 + d ≤ p0, and the alternative hypothesis is Ha: p1 + d &gt; p0 where P0 and P1 are the overall success rates in the control group and the investigational group respectively, and d is the non-inferiority margin. The analyses used Bayesian methodology. Should the posterior probability P (p1 - p0 &gt; -d | data) be at least 0.95, then the null non-inferiority hypothesis will be rejected, and non-inferiority of the investigational device to the control will be claimed.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin is 0.1.</non_inferiority_desc>
            <p_value>1.0</p_value>
            <p_value_desc>The posterior probably of non-inferiority was calculated and presented instead of the p-value.</p_value_desc>
            <method>Bayesian logistic model</method>
            <method_desc>The propensity score method was used to adjust possible effects on outcomes caused by differences in baseline characteristic due to non-randomization.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.099</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.038</ci_lower_limit>
            <ci_upper_limit>0.161</ci_upper_limit>
            <estimate_desc>The posterior mean of P1-P0, along with the corresponding 95% highest posterior density (HPD) interval was presented instead of the usual 95% CI.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority comparison of success rates in two treatment groups was a secondary objective of this trial. Superiority analysis was performed if non-inferiority was demonstrated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.999</p_value>
            <p_value_desc>The posterior probably of superiority was calculated and presented instead of the p-value.</p_value_desc>
            <method>Bayesian logistic model</method>
            <method_desc>The propensity score method was used to adjust possible effects on outcomes caused by differences in baseline characteristic due to non-randomization.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Disc Height Success</title>
        <description>Disc height was assessed by determining the Functional Spinal Unit (FSU) height. The rate of disc height success is reported as the percentage of participants whose disc height for each level based on either the anterior or posterior measurements met the following criterion: Postoperative Height - 6 Week Postoperative Height &gt;= -2mm</description>
        <time_frame>24 months</time_frame>
        <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable disc height success (FSU success) status at 24 months, which leads to 224 subjects in the investigational group and 164 subjects in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational</title>
            <description>PRESTIGE® LP Cervical Disc</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Disc Height Success</title>
          <description>Disc height was assessed by determining the Functional Spinal Unit (FSU) height. The rate of disc height success is reported as the percentage of participants whose disc height for each level based on either the anterior or posterior measurements met the following criterion: Postoperative Height - 6 Week Postoperative Height &gt;= -2mm</description>
          <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable disc height success (FSU success) status at 24 months, which leads to 224 subjects in the investigational group and 164 subjects in the control group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.5"/>
                    <measurement group_id="O2" value="95.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis H0: p1 + d ≤ p0, and the alternative hypothesis is Ha: p1 + d &gt; p0 where P0 and P1 are the overall success rates in the control group and the investigational group respectively, and d is the non-inferiority margin. The analyses used Bayesian methodology. Should the posterior probability P (p1 - p0 &gt; -d | data) be at least 0.95, then the null non-inferiority hypothesis will be rejected, and non-inferiority of the investigational device to the control will be claimed.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin is 0.1.</non_inferiority_desc>
            <p_value>0.992</p_value>
            <p_value_desc>The posterior probably of non-inferiority was calculated and presented instead of the p-value.</p_value_desc>
            <method>Bayesian logistic model</method>
            <method_desc>The propensity score method was used to adjust possible effects on outcomes caused by differences in baseline characteristic due to non-randomization.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.034</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.085</ci_lower_limit>
            <ci_upper_limit>0.021</ci_upper_limit>
            <estimate_desc>The posterior mean of P1-P0, along with the corresponding 95% highest posterior density (HPD) interval was presented instead of the usual 95% CI.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority comparison of success rates in two treatment groups was a secondary objective of this trial. Superiority analysis was performed if non-inferiority was demonstrated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.097</p_value>
            <p_value_desc>The posterior probably of superiority was calculated and presented instead of the p-value.</p_value_desc>
            <method>Bayesian logistic model</method>
            <method_desc>The propensity score method was used to adjust possible effects on outcomes caused by differences in baseline characteristic due to non-randomization.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neck Pain Success Rate</title>
        <description>Numerical rating scales were used to evaluate pain intensity and frequency. The pain score (0 min, 100 max) was derived by multiplying the numerical rating scores from the pain intensity (0-10, with a score of 0 representing &quot;no pain&quot; and a score of 10 representing &quot;pain as bad as it could be.&quot;) and frequency scales (0-10, with a score of 0 being &quot;pain none of the time&quot; and a score of 10 being &quot;pain all of the time&quot;). Neck pain success rate is reported as the percentage of participants whose neck pain improvement met: Preoperative Score - Postoperative Score &gt; 0.</description>
        <time_frame>24 months</time_frame>
        <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable neck pain success status at 24 months, which leads to 270 subjects in the investigational group and 219 subjects in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational</title>
            <description>PRESTIGE® LP Cervical Disc</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).</description>
          </group>
        </group_list>
        <measure>
          <title>Neck Pain Success Rate</title>
          <description>Numerical rating scales were used to evaluate pain intensity and frequency. The pain score (0 min, 100 max) was derived by multiplying the numerical rating scores from the pain intensity (0-10, with a score of 0 representing &quot;no pain&quot; and a score of 10 representing &quot;pain as bad as it could be.&quot;) and frequency scales (0-10, with a score of 0 being &quot;pain none of the time&quot; and a score of 10 being &quot;pain all of the time&quot;). Neck pain success rate is reported as the percentage of participants whose neck pain improvement met: Preoperative Score - Postoperative Score &gt; 0.</description>
          <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable neck pain success status at 24 months, which leads to 270 subjects in the investigational group and 219 subjects in the control group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3"/>
                    <measurement group_id="O2" value="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis H0: p1 + d ≤ p0, and the alternative hypothesis is Ha: p1 + d &gt; p0 where P0 and P1 are the overall success rates in the control group and the investigational group respectively, and d is the non-inferiority margin. The analyses used Bayesian methodology. Should the posterior probability P (p1 - p0 &gt; -d | data) be at least 0.95, then the null non-inferiority hypothesis will be rejected, and non-inferiority of the investigational device to the control will be claimed.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin is 0.1.</non_inferiority_desc>
            <p_value>1.0</p_value>
            <p_value_desc>The posterior probably of non-inferiority was calculated and presented instead of the p-value.</p_value_desc>
            <method>Bayesian logistic model</method>
            <method_desc>The propensity score method was used to adjust possible effects on outcomes caused by differences in baseline characteristic due to non-randomization.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.010</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.043</ci_lower_limit>
            <ci_upper_limit>0.023</ci_upper_limit>
            <estimate_desc>The posterior mean of P1-P0, along with the corresponding 95% highest posterior density (HPD) interval was presented instead of the usual 95% CI.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority comparison of success rates in two treatment groups was a secondary objective of this trial. Superiority analysis was performed if non-inferiority was demonstrated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.273</p_value>
            <p_value_desc>The posterior probably of superiority was calculated and presented instead of the p-value.</p_value_desc>
            <method>Bayesian logistic model</method>
            <method_desc>The propensity score method was used to adjust possible effects on outcomes caused by differences in baseline characteristic due to non-randomization.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arm Pain Success Rate</title>
        <description>Numerical rating scales were used to evaluate pain intensity and frequency. The pain score (0 min, 100 max) was derived by multiplying the numerical rating scores from the pain intensity (0-10, with a score of 0 representing &quot;no pain&quot; and a score of 10 representing &quot;pain as bad as it could be.&quot;) and frequency scales (0-10, with a score of 0 being &quot;pain none of the time&quot; and a score of 10 being &quot;pain all of the time&quot;). Arm pain success rate is reported as the percentage of participants whose arm pain improvement met: Preoperative Score - Postoperative Score &gt; 0.</description>
        <time_frame>24 months</time_frame>
        <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable arm pain success status at 24 months, which leads to 268 subjects in the investigational group and 219 subjects in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational</title>
            <description>PRESTIGE® LP Cervical Disc</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).</description>
          </group>
        </group_list>
        <measure>
          <title>Arm Pain Success Rate</title>
          <description>Numerical rating scales were used to evaluate pain intensity and frequency. The pain score (0 min, 100 max) was derived by multiplying the numerical rating scores from the pain intensity (0-10, with a score of 0 representing &quot;no pain&quot; and a score of 10 representing &quot;pain as bad as it could be.&quot;) and frequency scales (0-10, with a score of 0 being &quot;pain none of the time&quot; and a score of 10 being &quot;pain all of the time&quot;). Arm pain success rate is reported as the percentage of participants whose arm pain improvement met: Preoperative Score - Postoperative Score &gt; 0.</description>
          <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable arm pain success status at 24 months, which leads to 268 subjects in the investigational group and 219 subjects in the control group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3"/>
                    <measurement group_id="O2" value="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis H0: p1 + d ≤ p0, and the alternative hypothesis is Ha: p1 + d &gt; p0 where P0 and P1 are the overall success rates in the control group and the investigational group respectively, and d is the non-inferiority margin. The analyses used Bayesian methodology. Should the posterior probability P (p1 - p0 &gt; -d | data) be at least 0.95, then the null non-inferiority hypothesis will be rejected, and non-inferiority of the investigational device to the control will be claimed.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin is 0.1.</non_inferiority_desc>
            <p_value>1.0</p_value>
            <p_value_desc>The posterior probably of non-inferiority was calculated and presented instead of the p-value.</p_value_desc>
            <method>Bayesian logistic model</method>
            <method_desc>The propensity score method was used to adjust possible effects on outcomes caused by differences in baseline characteristic due to non-randomization.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.019</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.018</ci_lower_limit>
            <ci_upper_limit>0.058</ci_upper_limit>
            <estimate_desc>The posterior mean of P1-P0, along with the corresponding 95% highest posterior density (HPD) interval was presented instead of the usual 95% CI.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority comparison of success rates in two treatment groups was a secondary objective of this trial. Superiority analysis was performed if non-inferiority was demonstrated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.845</p_value>
            <p_value_desc>The posterior probably of superiority was calculated and presented instead of the p-value.</p_value_desc>
            <method>Bayesian logistic model</method>
            <method_desc>The propensity score method was used to adjust possible effects on outcomes caused by differences in baseline characteristic due to non-randomization.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Success Rate of SF-36 PCS</title>
        <description>Success rate of SF-36 Health Survey include two components: the success rate of a physical component summary (PCS) and the success rate of a mental component summary (MCS). The success of SF-36 PCS was defined as: Post Score - Pre Score &gt;= 0. The Success rate of SF-36 PCS is reported as the percentage of the participants who were classified as a success for SF-36 PCS.</description>
        <time_frame>24 months</time_frame>
        <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable SF-36 PCS success status at 24 months, which leads to 264 subjects in the investigational group and 216 subjects in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational</title>
            <description>PRESTIGE® LP Cervical Disc</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rate of SF-36 PCS</title>
          <description>Success rate of SF-36 Health Survey include two components: the success rate of a physical component summary (PCS) and the success rate of a mental component summary (MCS). The success of SF-36 PCS was defined as: Post Score - Pre Score &gt;= 0. The Success rate of SF-36 PCS is reported as the percentage of the participants who were classified as a success for SF-36 PCS.</description>
          <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable SF-36 PCS success status at 24 months, which leads to 264 subjects in the investigational group and 216 subjects in the control group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.7"/>
                    <measurement group_id="O2" value="86.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis H0: p1 + d ≤ p0, and the alternative hypothesis is Ha: p1 + d &gt; p0 where P0 and P1 are the overall success rates in the control group and the investigational group respectively, and d is the non-inferiority margin. The analyses used Bayesian methodology. Should the posterior probability P (p1 - p0 &gt; -d | data) be at least 0.95, then the null non-inferiority hypothesis will be rejected, and non-inferiority of the investigational device to the control will be claimed.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin is 0.1.</non_inferiority_desc>
            <p_value>0.936</p_value>
            <p_value_desc>The posterior probably of non-inferiority was calculated and presented instead of the p-value.</p_value_desc>
            <method>Bayesian logistic model</method>
            <method_desc>The propensity score method was used to adjust possible effects on outcomes caused by differences in baseline characteristic due to non-randomization.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.047</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.113</ci_lower_limit>
            <ci_upper_limit>0.021</ci_upper_limit>
            <estimate_desc>The posterior mean of P1-P0, along with the corresponding 95% highest posterior density (HPD) interval was presented instead of the usual 95% CI.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Success Rate of SF-36 MCS</title>
        <description>Success rate of SF-36 Health Survey include two components: the success rate of a physical component summary (PCS) and the success rate of a mental component summary (MCS). The success of SF-36 MCS were defined as: Post Score - Pre Score &gt;= 0. The Success rate of SF-36 MCS is reported as the percentage of the participants who were classified as a success for SF-36 MCS.</description>
        <time_frame>24 months</time_frame>
        <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable SF-36 MCS success status at 24 months, which leads to 264 subjects in the investigational group and 216 subjects in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational</title>
            <description>PRESTIGE® LP Cervical Disc</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rate of SF-36 MCS</title>
          <description>Success rate of SF-36 Health Survey include two components: the success rate of a physical component summary (PCS) and the success rate of a mental component summary (MCS). The success of SF-36 MCS were defined as: Post Score - Pre Score &gt;= 0. The Success rate of SF-36 MCS is reported as the percentage of the participants who were classified as a success for SF-36 MCS.</description>
          <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable SF-36 MCS success status at 24 months, which leads to 264 subjects in the investigational group and 216 subjects in the control group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.7"/>
                    <measurement group_id="O2" value="69.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis H0: p1 + d ≤ p0, and the alternative hypothesis is Ha: p1 + d &gt; p0 where P0 and P1 are the overall success rates in the control group and the investigational group respectively, and d is the non-inferiority margin. The analyses used Bayesian methodology. Should the posterior probability P (p1 - p0 &gt; -d | data) be at least 0.95, then the null non-inferiority hypothesis will be rejected, and non-inferiority of the investigational device to the control will be claimed.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin is 0.1.</non_inferiority_desc>
            <p_value>1.0</p_value>
            <p_value_desc>The posterior probably of non-inferiority was calculated and presented instead of the p-value.</p_value_desc>
            <method>Bayesian logistic model</method>
            <method_desc>The propensity score method was used to adjust possible effects on outcomes caused by differences in baseline characteristic due to non-randomization.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.105</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.020</ci_lower_limit>
            <ci_upper_limit>0.190</ci_upper_limit>
            <estimate_desc>The posterior mean of P1-P0, along with the corresponding 95% highest posterior density (HPD) interval was presented instead of the usual 95% CI.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority comparison of success rates in two treatment groups was a secondary objective of this trial. Superiority analysis was performed if non-inferiority was demonstrated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.992</p_value>
            <p_value_desc>The posterior probably of superiority was calculated and presented instead of the p-value.</p_value_desc>
            <method>Bayesian logistic model</method>
            <method_desc>The propensity score method was used to adjust possible effects on outcomes caused by differences in baseline characteristic due to non-randomization.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gait Success Rate</title>
        <description>Patient's gait was assessed by using Nurick's classification, and indicated either as normal or graded on a scale of 0 to 5. Success was defined as maintenance or improvement in the postoperative status as compared to the preoperative condition: Preoperative Score - Postoperative Score &gt;= 0. The gait success rate is reported as the percentage of participants who had gait success.</description>
        <time_frame>24 months</time_frame>
        <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable gait success status at 24 months, which leads to 270 subjects in the investigational group and 220 subjects in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational</title>
            <description>PRESTIGE® LP Cervical Disc</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).</description>
          </group>
        </group_list>
        <measure>
          <title>Gait Success Rate</title>
          <description>Patient's gait was assessed by using Nurick's classification, and indicated either as normal or graded on a scale of 0 to 5. Success was defined as maintenance or improvement in the postoperative status as compared to the preoperative condition: Preoperative Score - Postoperative Score &gt;= 0. The gait success rate is reported as the percentage of participants who had gait success.</description>
          <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable gait success status at 24 months, which leads to 270 subjects in the investigational group and 220 subjects in the control group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3"/>
                    <measurement group_id="O2" value="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Operative Time</title>
        <description>Operative time was recorded from skin incision to wound closure.</description>
        <time_frame>Time of operation, approximately 1.5 hrs.</time_frame>
        <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable information for operative time, which leads to 280 subjects in the investigational group and 265 subjects in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational</title>
            <description>PRESTIGE® LP Cervical Disc</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).</description>
          </group>
        </group_list>
        <measure>
          <title>Operative Time</title>
          <description>Operative time was recorded from skin incision to wound closure.</description>
          <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable information for operative time, which leads to 280 subjects in the investigational group and 265 subjects in the control group.</population>
          <units>hrs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.6"/>
                    <measurement group_id="O2" value="1.4" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority comparison of the operative time in two treatment groups was assessed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>The posterior probably of superiority was calculated and presented instead of the p-value.</p_value_desc>
            <method>Bayesian logistic model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Loss</title>
        <time_frame>During the time of operation, approximately 1.5 hours.</time_frame>
        <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable information for blood loss, which leads to 278 subjects in the investigational group and 263 subjects in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational</title>
            <description>PRESTIGE® LP Cervical Disc</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Loss</title>
          <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable information for blood loss, which leads to 278 subjects in the investigational group and 263 subjects in the control group.</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5" spread="73.5"/>
                    <measurement group_id="O2" value="57.5" spread="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority comparison of the blood loss in two treatment groups was assessed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.769</p_value>
            <p_value_desc>The posterior probably of superiority was calculated and presented instead of the p-value.</p_value_desc>
            <method>Bayesian logistic model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Stay</title>
        <time_frame>During the time of hospital stay, average of 1 day.</time_frame>
        <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable information for hospital stay, which leads to 280 subjects in the investigational group and 265 subjects in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational</title>
            <description>PRESTIGE® LP Cervical Disc</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Stay</title>
          <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable information for hospital stay, which leads to 280 subjects in the investigational group and 265 subjects in the control group.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.5"/>
                    <measurement group_id="O2" value="1.0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority comparison of the hospital stay in two treatment groups was assessed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.273</p_value>
            <p_value_desc>The posterior probably of superiority was calculated and presented instead of the p-value.</p_value_desc>
            <method>Bayesian logistic model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Secondary Surgery at Index Level</title>
        <description>Secondary surgical procedures at the index level included revisions, removals, supplemental fixations and reoperations. Rate of secondary surgery at index level is reported as percentage of patients who had secondary surgeries at index level.</description>
        <time_frame>24 months post-operation</time_frame>
        <population>For this endpoint, the analysis consists of all subjects in the primary analysis dataset with 280 subjects in the investigational control and 265 subjects in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational</title>
            <description>PRESTIGE® LP Cervical Disc</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Secondary Surgery at Index Level</title>
          <description>Secondary surgical procedures at the index level included revisions, removals, supplemental fixations and reoperations. Rate of secondary surgery at index level is reported as percentage of patients who had secondary surgeries at index level.</description>
          <population>For this endpoint, the analysis consists of all subjects in the primary analysis dataset with 280 subjects in the investigational control and 265 subjects in the control group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Neck Disability Index Score From Baseline</title>
        <description>The self-administered Neck Disability Index (NDI) Questionnaire was used to assess patient neck pain and ability to function. The NDI scale ranges from 0-100. The best score is 0 (no disability) and worst is 100 (maximum disability). Change of NDI was defined as NDI at 24 month minus NDI at baseline.</description>
        <time_frame>Baseline and 24 months post-operation</time_frame>
        <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable NDI score at both baseline and 24 months, which leads to 270 subjects in the investigational group and 219 subjects in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational</title>
            <description>PRESTIGE® LP Cervical Disc</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Neck Disability Index Score From Baseline</title>
          <description>The self-administered Neck Disability Index (NDI) Questionnaire was used to assess patient neck pain and ability to function. The NDI scale ranges from 0-100. The best score is 0 (no disability) and worst is 100 (maximum disability). Change of NDI was defined as NDI at 24 month minus NDI at baseline.</description>
          <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable NDI score at both baseline and 24 months, which leads to 270 subjects in the investigational group and 219 subjects in the control group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NDI at baseline (n=280, 264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.5" spread="14.7"/>
                    <measurement group_id="O2" value="56.4" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NDI at 24 months (n=270, 220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="18.3"/>
                    <measurement group_id="O2" value="22.4" spread="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NDI change (n=270, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.7" spread="21.0"/>
                    <measurement group_id="O2" value="-33.9" spread="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Neck Pain Score From Baseline</title>
        <description>Numerical rating scales were used to evaluate neck pain intensity and frequency. Patients rated their neck pain intensity on a scale from 0-10, with a score of 0 representing &quot;no pain&quot; and a score of 10 representing &quot;pain as bad as it could be.&quot; Similarly, patients recorded their neck pain frequency on a scale from 0-10, with a score of 0 being &quot;pain none of the time&quot; and a score of 10 being &quot;pain all of the time.&quot; The total neck pain score (0 to100) was the product of pain intensity and frequency scores. Change of neck pain score was defined as neck pain score at 24 months minus neck pain score at baseline.</description>
        <time_frame>Baseline and 24 months post-operation</time_frame>
        <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable neck pain score at both baseline and 24 months, which leads to 270 subjects in the investigational group and 219 subjects in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational</title>
            <description>PRESTIGE® LP Cervical Disc</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Neck Pain Score From Baseline</title>
          <description>Numerical rating scales were used to evaluate neck pain intensity and frequency. Patients rated their neck pain intensity on a scale from 0-10, with a score of 0 representing &quot;no pain&quot; and a score of 10 representing &quot;pain as bad as it could be.&quot; Similarly, patients recorded their neck pain frequency on a scale from 0-10, with a score of 0 being &quot;pain none of the time&quot; and a score of 10 being &quot;pain all of the time.&quot; The total neck pain score (0 to100) was the product of pain intensity and frequency scores. Change of neck pain score was defined as neck pain score at 24 months minus neck pain score at baseline.</description>
          <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable neck pain score at both baseline and 24 months, which leads to 270 subjects in the investigational group and 219 subjects in the control group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neck Pain at baseline (n=280, 264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.0" spread="20.8"/>
                    <measurement group_id="O2" value="69.3" spread="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neck Pain at 24 months (n=270, 220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="19.2"/>
                    <measurement group_id="O2" value="16.6" spread="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neck Pain Change (n=270, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.6" spread="28.2"/>
                    <measurement group_id="O2" value="-52.1" spread="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Arm Pain Score From Baseline</title>
        <description>Numerical rating scales were also used to evaluate arm pain intensity and frequency. Patients rated their arm pain intensity on a scale from 0-10, with a score of 0 representing &quot;no pain&quot; and a score of 10 representing &quot;pain as bad as it could be.&quot; Similarly, patients recorded their arm pain frequency on a scale from 0-10, with a score of 0 being &quot;pain none of the time&quot; and a score of 10 being &quot;pain all of the time.&quot; The total arm pain score (0 to 100) was the product of pain intensity and frequency scores. Change of arm pain score was defined as arm pain score at 24 months minus arm pain score at baseline.</description>
        <time_frame>Baseline and 24 months post-operation</time_frame>
        <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable arm pain score at both baseline and 24 months, which leads to 268 subjects in the investigational group and 219 subjects in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational</title>
            <description>PRESTIGE® LP Cervical Disc</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Arm Pain Score From Baseline</title>
          <description>Numerical rating scales were also used to evaluate arm pain intensity and frequency. Patients rated their arm pain intensity on a scale from 0-10, with a score of 0 representing &quot;no pain&quot; and a score of 10 representing &quot;pain as bad as it could be.&quot; Similarly, patients recorded their arm pain frequency on a scale from 0-10, with a score of 0 being &quot;pain none of the time&quot; and a score of 10 being &quot;pain all of the time.&quot; The total arm pain score (0 to 100) was the product of pain intensity and frequency scores. Change of arm pain score was defined as arm pain score at 24 months minus arm pain score at baseline.</description>
          <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable arm pain score at both baseline and 24 months, which leads to 268 subjects in the investigational group and 219 subjects in the control group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arm pain score at baseline (n=280, 264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.6" spread="26.3"/>
                    <measurement group_id="O2" value="62.4" spread="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm pain score at 24 months (n=268, 220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="18.3"/>
                    <measurement group_id="O2" value="14.2" spread="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm pain score change (n=268, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.0" spread="31.4"/>
                    <measurement group_id="O2" value="-48.0" spread="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of General Health Status -- SF-36 PCS From Baseline</title>
        <description>The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) was used to assess general health status. The SF-36 results were summarized into two components, a physical component summary (PCS) and a mental component summary (MCS). The score for PCS was between 0 and 100, with higher scores denoting better quality of life. Change of SF-36 PCS score was defined as PCS score at 24 months minus PCS score at baseline.</description>
        <time_frame>Baseline and 24 months post-operation</time_frame>
        <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable PCS score at both baseline and 24 months, which leads to 264 subjects in the investigational group and 216 subjects in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational</title>
            <description>PRESTIGE® LP Cervical Disc</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).</description>
          </group>
        </group_list>
        <measure>
          <title>Change of General Health Status -- SF-36 PCS From Baseline</title>
          <description>The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) was used to assess general health status. The SF-36 results were summarized into two components, a physical component summary (PCS) and a mental component summary (MCS). The score for PCS was between 0 and 100, with higher scores denoting better quality of life. Change of SF-36 PCS score was defined as PCS score at 24 months minus PCS score at baseline.</description>
          <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable PCS score at both baseline and 24 months, which leads to 264 subjects in the investigational group and 216 subjects in the control group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SF-36 PCS at baseline (n=279, 263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2" spread="7.4"/>
                    <measurement group_id="O2" value="32.0" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-36 PCS at 24 months (n=265, 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.6" spread="11.4"/>
                    <measurement group_id="O2" value="44.4" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-36 PCS change (n=264, 216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="11.6"/>
                    <measurement group_id="O2" value="11.9" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of General Health Status -- SF-36 MCS From Baseline</title>
        <description>The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) was used to assess general health status. The SF-36 results were summarized into two components, a physical component summary (PCS) and a mental component summary (MCS). The score for MCS was between 0 and 100, with higher scores denoting better quality of life. Change of SF-36 MCS score was defined as MCS score at 24 months minus MCS score at baseline.</description>
        <time_frame>Baseline and 24 months post-operation</time_frame>
        <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable MCS score at both baseline and 24 months, which leads to 264 subjects in the investigational group and 216 subjects in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational</title>
            <description>PRESTIGE® LP Cervical Disc</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).</description>
          </group>
        </group_list>
        <measure>
          <title>Change of General Health Status -- SF-36 MCS From Baseline</title>
          <description>The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) was used to assess general health status. The SF-36 results were summarized into two components, a physical component summary (PCS) and a mental component summary (MCS). The score for MCS was between 0 and 100, with higher scores denoting better quality of life. Change of SF-36 MCS score was defined as MCS score at 24 months minus MCS score at baseline.</description>
          <population>For this endpoint, the analysis consists of subjects in the primary analysis dataset with evaluable MCS score at both baseline and 24 months, which leads to 264 subjects in the investigational group and 216 subjects in the control group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SF-36 MCS at baseline (n=279, 263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5" spread="11.5"/>
                    <measurement group_id="O2" value="42.7" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-36 MCS at 24 months (n=265, 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6" spread="9.6"/>
                    <measurement group_id="O2" value="50.2" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-36 MCS change (n=264, 216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="12.3"/>
                    <measurement group_id="O2" value="7.2" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 24 months</time_frame>
      <desc>The adverse events, originally collected in FDA proposed categories, were grouped into organ systems.</desc>
      <group_list>
        <group group_id="E1">
          <title>Investigational</title>
          <description>PRESTIGE® LP Cervical Disc</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Control patients who received ACDF fusion treatment from a previous IDE trial (NCT00642876).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Disorders</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="280"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia/Dysphonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="22" subjects_affected="13" subjects_at_risk="280"/>
                <counts group_id="E2" events="20" subjects_affected="12" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Implant Events</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="17" subjects_affected="11" subjects_at_risk="280"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="280"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Wound (Non-Infectious)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="280"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Spinal Events</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="280"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other Pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="280"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Heterotopic Ossification</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="280"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Neck and/or Arm Pain</sub_title>
                <counts group_id="E1" events="52" subjects_affected="37" subjects_at_risk="280"/>
                <counts group_id="E2" events="36" subjects_affected="24" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Non-Union</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Spinal Events</sub_title>
                <counts group_id="E1" events="77" subjects_affected="40" subjects_at_risk="280"/>
                <counts group_id="E2" events="54" subjects_affected="31" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other Pain</sub_title>
                <counts group_id="E1" events="38" subjects_affected="27" subjects_at_risk="280"/>
                <counts group_id="E2" events="21" subjects_affected="16" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" events="52" subjects_affected="35" subjects_at_risk="280"/>
                <counts group_id="E2" events="32" subjects_affected="27" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Spinal Events</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other Pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="280"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="280"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urogenital</sub_title>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="280"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="280"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Dysphagia/Dysphonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="242" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="211" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Disorders</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="280"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="280"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia/Dysphonia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="280"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="33" subjects_affected="25" subjects_at_risk="280"/>
                <counts group_id="E2" events="48" subjects_affected="30" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Implant Events</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="280"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="280"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="280"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="280"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="40" subjects_affected="28" subjects_at_risk="280"/>
                <counts group_id="E2" events="29" subjects_affected="22" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anatomical/technical difficulty</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="280"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other Pain</sub_title>
                <counts group_id="E1" events="23" subjects_affected="17" subjects_at_risk="280"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" events="49" subjects_affected="44" subjects_at_risk="280"/>
                <counts group_id="E2" events="34" subjects_affected="30" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Wound(Non-Infectious)</sub_title>
                <counts group_id="E1" events="29" subjects_affected="20" subjects_at_risk="280"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="280"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="280"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Heterotopic Ossification</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="280"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Neck and/or Arm Pain</sub_title>
                <counts group_id="E1" events="223" subjects_affected="125" subjects_at_risk="280"/>
                <counts group_id="E2" events="177" subjects_affected="113" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Non-Union</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="280"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other Pain</sub_title>
                <counts group_id="E1" events="121" subjects_affected="88" subjects_at_risk="280"/>
                <counts group_id="E2" events="122" subjects_affected="80" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Spinal Events</sub_title>
                <counts group_id="E1" events="91" subjects_affected="50" subjects_at_risk="280"/>
                <counts group_id="E2" events="42" subjects_affected="27" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Spinal Events</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia/Dysphonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" events="190" subjects_affected="116" subjects_at_risk="280"/>
                <counts group_id="E2" events="185" subjects_affected="92" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="280"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other Pain</sub_title>
                <counts group_id="E1" events="50" subjects_affected="43" subjects_at_risk="280"/>
                <counts group_id="E2" events="35" subjects_affected="32" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Spinal Events</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="280"/>
                <counts group_id="E2" events="23" subjects_affected="16" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Urogenital</sub_title>
                <counts group_id="E1" events="22" subjects_affected="16" subjects_at_risk="280"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia/Dysphonia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="280"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="25" subjects_affected="20" subjects_at_risk="280"/>
                <counts group_id="E2" events="22" subjects_affected="16" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="280"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Other Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="280"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Department</name_or_title>
      <organization>Medtronic Spinal</organization>
      <phone>1800-876-3133 ext 6068</phone>
      <email>msbkclinicalresearch@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

